New Recommendations Improve Accuracy of HER2 Status Designation

Jason Harris
Published: Friday, Aug 17, 2018
Antonio C. Wolff, MD

Antonio C. Wolff, MD

The guidelines for establishing HER2 status for patients with breast cancer with unclear results on initial testing have been fine-tuned in an update that the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) recently issued.

Some Recommendations Changed

The panel has changed a recommendation regarding repeat HER2 testing of a surgical specimen. If the initial core biopsy is negative, a repeat test on the excision specimen is now optional rather than mandatory. Hammond said that clinical evidence shows the result is unlikely to change with a second test and may result in misdiagnosis.

“If you do a lot of repeat testing on the same sample, statistically what you do is increase the [odds] that you will have the wrong answer just by chance,” she said. “Repeat testing, in and of itself, is not a good idea.

Table 1. Clinical Questions Addressed in Updated HER2 Guidelines2

Table 1. Clinical Questions Addressed in Updated HER2 Guidelines2
The panel also recommends that the same institution should perform the concomitant review to ensure “parallel interpretation and quality of the 2 assays.” Wolff said that very few group 2 specimens will be IHC 3+ and so will not be confirmed as HER2 positive. Most group 4 specimens will be confirmed HER2 negative without the need for additional testing using alternative probes, he added.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication